Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
COM
Direxion Auspice Broad Commodity Strategy ETF
$29.43
+0.2%
$28.59
$27.56
$31.62
$261.93M0.1947,115 shs91,899 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
C$1.47
-1.3%
C$1.44
C$1.20
C$4.49
C$110.87M1.4976,504 shs14,646 shs
SCYB
Schwab High Yield Bond ETF
$51.27
+0.3%
$51.63
$48.50
$52.35
$140.99M0.3142,962 shs32,830 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
COM
Direxion Auspice Broad Commodity Strategy ETF
0.00%-0.10%+3.99%+5.77%-5.76%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%-75.46%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.00%+2.08%+1.38%-10.37%-15.52%
SCYB
Schwab High Yield Bond ETF
0.00%+0.61%-1.71%-1.54%+5,126,999,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
COM
Direxion Auspice Broad Commodity Strategy ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.77 of 5 stars
3.50.00.00.00.01.70.0
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.6801 of 5 stars
3.50.00.00.01.20.00.0
SCYB
Schwab High Yield Bond ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
COM
Direxion Auspice Broad Commodity Strategy ETF
0.00
N/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.75∞ Upside
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.00
BuyC$6.00308.16% Upside
SCYB
Schwab High Yield Bond ETF
N/AN/AN/AN/A

Current Analyst Ratings

Latest ONC, SCYB, COM, and MDNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$3.00
(Data available from 4/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
COM
Direxion Auspice Broad Commodity Strategy ETF
N/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AC$0.35 per share4.22C$0.37 per shareN/A
SCYB
Schwab High Yield Bond ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
COM
Direxion Auspice Broad Commodity Strategy ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$27.75M-C$0.41N/AN/AN/A-102.66%-55.47%5/3/2024 (Estimated)
SCYB
Schwab High Yield Bond ETF
N/AN/A0.00N/AN/AN/AN/AN/A

Latest ONC, SCYB, COM, and MDNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.15-C$0.05+C$0.10-C$0.05N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
COM
Direxion Auspice Broad Commodity Strategy ETF
$2.538.60%N/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AN/AN/AN/A
SCYB
Schwab High Yield Bond ETF
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
COM
Direxion Auspice Broad Commodity Strategy ETF
N/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
1.54
9.01
8.86
SCYB
Schwab High Yield Bond ETF
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
COM
Direxion Auspice Broad Commodity Strategy ETF
N/A8.90 millionN/ANot Optionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
2975.42 millionN/ANot Optionable
SCYB
Schwab High Yield Bond ETF
N/A2.75 millionN/ANot Optionable

ONC, SCYB, COM, and MDNA Headlines

New MarketBeat Followers Over Time

Top Headlines

All Headlines

Company Descriptions

Direxion Auspice Broad Commodity Strategy ETF

NYSEARCA:COM
The Direxion Auspice Broad Commodity Strategy ETF (COM) is an exchange-traded fund that is based on the Auspice Broad Commodity index. The fund tracks a broad-market index consisting of 12 commodity futures contracts, weighted by historical volatility, which can toggle to cash based on momentum. The fund will also hold short-term fixed income securities as collateral. COM was launched on Mar 30, 2017 and is managed by Direxion.
Medicenna Therapeutics logo

Medicenna Therapeutics

NASDAQ:MDNA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Oncolytics Biotech logo

Oncolytics Biotech

TSE:ONC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Schwab High Yield Bond ETF

NYSEARCA:SCYB
The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab.